NCT06423911View on ClinicalTrials.gov

Study of Olverembatinib (HQP1351) in Patients With CP-CML

PHASE3RecruitingINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Chronic Myeloid LeukemiaCMLCML, Chronic Phase
Interventions
DRUG

olverembatinib

olverembatinib QOD

DRUG

Bosutinib

Bosutnib QD

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY